Why Seattle Genetics Stock Skyrocketed 102% in 2019
Shares of Seattle Genetics (NASDAQ: SGEN), a pioneer in developing antibody-drug conjugates (ADCs) to treat cancer, soared 102% in 2019, according to data from S&P Global Market Intelligence. That performance made it one of the year's better-performing large-cap healthcare stocks. For context, the S&P 500 index returned 31.5% in 2019.
(In 2020, Seattle Genetics stock is down 1.7% through Jan. 10, compared with the S&P 500's 1.1% return.)
Image source: Getty Images.
Source Fool.com